153034-78-7

Basic information

• Product Name: 2-Fluoro-3-iodo-5-methylpyridine
• Synonyms: 2-fluoro-3-iodo-5-methylpyridine;2-FLUORO-3-IODO-5-PICOLINE;2-fluoro-3-iodo-5-fluoropyridine;2-FLUORO-3-IODO-5-PICOLINE (2-FLUORO-3-IODO-5-METHYLPYRIDINE);2,5-difluoro-3-iodopyridine;2-Fluoro-3-iodo-5-picolin
• CAS NO: 153034-78-7
• Molecular Formula: C₆H₅FIN
• Molecular Weight: 237.01
• Product Categories: Pyridine;Halides;Pyridines;Boronic Acid;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Fluorine series
• Mol File: 153034-78-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: 38-42°C
• Boiling Point: 252.471 °C at 760 mmHg
• Flash Point: >110℃
• Appearance: /
• Density: 1.893 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -2.16±0.20(Predicted)
• CAS DataBase Reference: 2-Fluoro-3-iodo-5-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-3-iodo-5-methylpyridine(153034-78-7)
• EPA Substance Registry System: 2-Fluoro-3-iodo-5-methylpyridine(153034-78-7)

Safety Data

• Hazard Codes: T,Xi
• Statements: 36/37/38-36-41-22
• Safety Statements: 26-36-39
• WGK Germany: 3
• Hazardous Substances Data: 153034-78-7(Hazardous Substances Data)

Usage

Uses

2-Fluoro-3-iodo-5-methylpyridine is a tri-substituted pyridine used in the preparation of biologically active compounds such as protein kinase inhibitors.

Upstream product

• 2369-19-9 2-fluoro-5-methylpyridine 
• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 851607-25-5 2-fluoro-5-methyl-pyridin-3-yllithium 

Downstream Products

• 153034-94-7 2-Fluoro-4-iodo-5-methylpyridine 
• 450840-65-0 4-(3-chlorophenyl)-2-fluoro-5-methylpyridine 
• 450840-75-2 4-(3-chlorophenyl)-5-methyl-2-pyridinecarbonitrile 
• 777096-60-3 4-(3,5-dichloro-phenyl)-2-fluoro-5-methyl-pyridine 
• 450840-70-7 5-(bromomethyl)-4-(3-chlorophenyl)-2-fluoropyridine 
• 777096-61-4 2-fluoro-5-methyl-4-(3-trifluoromethyl-phenyl)-pyridine 
• 777096-62-5 4-(3,5-dichloro-phenyl)-5-methyl-pyridine-2-carbonitrile 
• 777096-64-7 4-(3-chloro-phenyl)-5-methyl-6-oxo-1,6-dihydro-pyridine-2-carbonitrile 
• 777096-67-0 4-(3-chloro-phenyl)-1,5-dimethyl-6-oxo-1,6-dihydro-pyridine-2-carbonitrile 
• 777096-63-6 5-methyl-4-(3-trifluoromethyl-phenyl)-pyridine-2-carbonitrile 
• 777096-65-8 4-(3,5-dichloro-phenyl)-5-methyl-6-oxo-1,6-dihydro-pyridine-2-carbonitrile 
• 777096-68-1 4-(3,5-dichloro-phenyl)-1,5-dimethyl-6-oxo-1,6-dihydro-pyridine-2-carbonitrile 
• 777096-69-2 1,5-dimethyl-6-oxo-4-(3-trifluoromethyl-phenyl)-1,6-dihydro-pyridine-2-carbonitrile 
• 777096-66-9 5-methyl-6-oxo-4-(3-trifluoromethyl-phenyl)-1,6-dihydro-pyridine-2-carbonitrile 

Relevant articles and documents

HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the programmed necrosis pathway.

Synthesis, radiolabeling and preliminary in vivo evaluation of multimodal radiotracers for PET imaging and targeted radionuclide therapy of pigmented melanoma

Melanin pigment represents an attractive target to address specific treatment to melanoma cells, such as cytotoxic radionuclides. However, less than half of the patients have pigmented metastases. Hence, specific marker is required to stratify this patient population before proceeding with melanin-targeted radionuclide therapy. In such a context, we developed fluorinated analogues of a previously studied melanin-targeting ligand, N-(2-diethylaminoethyl)-6-iodoquinoxaline-2-carboxamide (ICF01012). These latter can be labeled either with 18F or 131I/125I for positron emission tomography imaging (melanin-positive patient selection) and targeted radionuclide therapy purposes. Here we describe the syntheses, radiosyntheses and preclinical evaluations on melanoma-bearing mice model of several iodo- and fluoro(hetero)aromatic derivatives of the ICF01012 scaffold. After preliminary planar gamma scintigraphic and positron emission tomography imaging evaluations, [125I]- and [18F]-N-[2-(diethylamino)ethyl]-4-fluoro-3-iodobenzamides ([125I]4, [18F]4) were found to be chemically and biologically stable with quite similar tumor uptakes at 1 h p.i. (9.7 ± 2.6% ID/g and 6.8 ± 1.9% ID/g, respectively).

[1H- PYRAZOLO [3, 4-B] PYRIDINE-4-YL] -PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA

The present invention relates to compounds of formula (I) and (IA) useful as inhibitors of protein kinase (1a). The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. (a) : in particular protein kinase C theta, wherein A and A' are independently -N- or -C(R+) -. Ring B is five- or six-membered saturated carbocyclic or heterocyclic R1, R2, R3, R4, R5, R6, R7, x and y are as described herein.